Macrocyclic tak1 inhibitors

A compound according to formula (I)

• or a tautomer thereof,
• wherein,
• A is a 6 membered aromatic ring or 5 to 6 membered heteroaromatic ring comprising 1 or 2 atoms selected from the group consisting of N, S and O;
• W1, W2, W3 are independently selected from CH and N;
• X is linear C2-8alkylene, optionally substituted with one or more groups independently selected from halogen;
• OH;
• C3-6cycloalkyl;
• C1-6alkyl optionally substituted with one or more halogen or OH;
• and two groups attached to the same carbon atom in the linear C2-8alkylene which together with the atom in the linear C2-8alkylene form a 3- or 4-membered cycloalkyl group;
• and/or wherein optionally one or more carbon atoms in the alkylene is replaced by a group independently selected from O, NH and S;
• Y is NH or O;
• R1 and R2 are independently selected from H;
• C1-6alkyl;
• C2-6alkenyl;
• C2-6alkynyl;
• OC1-6 alkyl;
• OC2-6alkenyl;
• OC2-6alkynyl;
• —Ra, C(O)Ra;
• C(O)ORa;
• OCRa;
• OC(O)(Ra);
• —C1-6 alkylene-Ra;
• —C(O)C1-6alkylene-Ra;
• —C(O)OC1-6alkylene-Ra;
• —OC1-6alkylene-Ra;
• OC(O)C1-6alkylene-Ra;
• and —Rb, wherein said alkyl, alkenyl, or alkynyl is optionally substituted with one or more Rb groups;
• R3 is H, halogen, OH, C1-6alkyl or OC1-6alkyl, wherein said alkyl is optionally substituted with one or more halogen;
• wherein,
• Ra is selected from C3-8cycloalkyl or 3 to 12 membered heterocycle comprising one, two or three atoms selected from the group consisting of N, S and O;
• said cycloalkyl or heterocycle optionally being bridged by C1-4alkylene and/or substituted by one or more groups independently selected from C1-4alkyl;
• 3 to 6 membered heterocycle comprising one, two or three atoms selected from the group consisting of N, S and O;
• C3-6cycloalkyl;
• OC1-4alkyl;
• O-(3 to 6 membered heterocycle comprising one, two or three atoms selected from the group consisting of N, S and O);
• OC3-6cycloalkyl;
• C(O)C1-4alkyl;
• C(O)OC1-4alkyl;
• OC(O)C1-4alkyl;
• C(O)NH2;
• and —C1-4alkylene-OC1-4alkyl;
• wherein said alkyl, alkylene, heterocycle or cycloalkyl at Ra is optionally substituted by one or more groups independently selected from halogen;
• OH;
• O;
• SH;
• NH2;
• NHC1-4alkyl;
• or N(C1-4alkyl)2;
• and
• Each Rb is independently selected from C(O)Rc;
• C(O)ORc;
• OC(O)Rc;
• SRc;
• SO2Rc;
• NO2;
• CN;
• NRcRd;
• N(Rc)SO2C1-3alkyl;
• N(Rc)C(O)Rd;
• C(O)NRcRd;
• SO2NRcRd, halogen;
• SH;
• NH2;
• and OH;
• said alkyl optionally being substituted with one or more groups independently selected from halogen, SH, NH2 and OH and/or wherein optionally one or more carbon atoms in the alkyl is replaced by a group independently selected from O, NH and S;
• and
• Rc and Rd are independently selected from H;
• C1-6alkyl;
• C2-6alkenyl;
• C2-6alkynyl;
• —C1-4alkylene-OC1-4alkyl;
• and C3-8cycloalkyl;
• said alkyl, alkylene, alkenyl, alkynyl or cycloalkyl optionally being substituted with one or more groups selected from halogen, SH, NH2, OH and ═O, and/or wherein optionally one or more carbon atoms in the alkyl is replaced by an atom independently selected from O, N and S;
• or a pharmaceutically acceptable salt or solvate thereof.